Esmolol Hydrochloride | CAS# 81161-17-3 | Beta Adrenergic Antagonist

Esmolol Hydrochloride
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317785

CAS#: 81161-17-3

Description: Esmolol Hydrochloride is the hydrochloride salt form of esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic activity. Esmolol hydrochloride competitively blocks beta-1 adrenergic receptors in cardiac muscle and reduces the contractility and cardiac rate of heart muscle, thereby decreasing cardiac output and myocardial oxygen demands. This agent also decreases sympathetic output centrally and blocks renin secretion. At higher doses, esmolol hydrochloride also blocks beta-2 receptors located in bronchial and vascular smooth muscle, thereby leading to smooth muscle relaxation.

Chemical Structure

Esmolol Hydrochloride

CAS# 81161-17-3

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 317785
Name: Esmolol Hydrochloride
CAS#: 81161-17-3
Chemical Formula: C16H26ClNO4
Exact Mass: 0.00
Molecular Weight: 331.840
Elemental Analysis: C, 57.91; H, 7.90; Cl, 10.68; N, 4.22; O, 19.29

Price and Availability

Size	Price	Availability
1g	USD 250	2 weeks
2g	USD 400	2 weeks
5g	USD 750	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Esmolol Hydrochloride; Esmolol HCL; Brevibloc; 81161-17-3; ASL-8052; Asl 8052; ASL 8052; Brevibloc; esmolol; esmolol hydrochloride;

IUPAC/Chemical Name: methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate;hydrochloride

InChi Key: GEKNCWBANDDJJL-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H25NO4.ClH/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3;/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3;1H

SMILES Code: CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Esmolol hydrochloride is a beta adrenergic receptor blocker.
In vitro activity:	The results indicated that esmolol reversibly inhibited I(Na) in a concentration-dependent manner, with an IC50 of 74.2 +/- 0.60 micromol l(-1) with a Hill coefficient of 1.02 +/- 0.04. This inhibition was voltage- and frequency-dependent. Reference: Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702. https://pubmed.ncbi.nlm.nih.gov/17235414/
In vivo activity:	Brain histology showed a significant reduction in cortical neuronal degeneration/necrosis in the esmolol group compared to the control one (mean score 0.3 vs. 1.3, p = 0.03, Fig. 3A), while only a trend was present in the hippocampal region (mean score 1 vs. 2, p = 0.11, Fig. 3B). A marked reduction of microglial activation in the hippocampus was also observed after treatment with esmolol compared to control (mean % 6 vs. 2, p < 0.001, Fig. 3C). Significantly lower circulating levels of NSE were measured in esmolol animals compared to controls at 96 h after resuscitation (median 2.2 vs. 21, p < 0.0001, Fig. 4A). Reference: Sci Rep. 2021; 11: 10635. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138021/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	63.7	191.87
	DMF	25.0	75.34
	Ethanol	45.5	137.11
	PBS (pH 7.2)	10.0	30.14
	Water	58.0	174.78

Preparing Stock Solutions

The following data is based on the product molecular weight 331.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Deng CY, Lin SG, Zhang WC, Kuang SJ, Qian WM, Wu SL, Shan ZX, Yang M, Yu XY. Esmolol inhibits Na+ current in rat ventricular myocytes. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702. doi: 10.1358/mf.2006.28.10.1037498. PMID: 17235414. 2. Gorelik J, Vodyanoy I, Shevchuk AI, Diakonov IA, Lab MJ, Korchev YE. Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay. FEBS Lett. 2003 Jul 31;548(1-3):74-8. doi: 10.1016/s0014-5793(03)00743-9. PMID: 12885410. 3. Ruggeri L, Nespoli F, Ristagno G, Fumagalli F, Boccardo A, Olivari D, Affatato R, Novelli D, De Giorgio D, Romanelli P, Minoli L, Cucino A, Babini G, Staszewsky L, Zani D, Pravettoni D, Belloli A, Scanziani E, Latini R, Magliocca A. Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. Sci Rep. 2021 May 20;11(1):10635. doi: 10.1038/s41598-021-90202-w. PMID: 34017043; PMCID: PMC8138021. 4. Hoareau GL, Beyer CA, Caples CM, Spruce MW, Gilbert Z, Grayson JK, Neff LP, Williams TK, Johnson MA. Esmolol reduces myocardial injury induced by resuscitative endovascular balloon occlusion of the aorta (REBOA) in a porcine model of hemorrhagic shock. Injury. 2020 Oct;51(10):2165-2171. doi: 10.1016/j.injury.2020.07.005. Epub 2020 Jul 3. PMID: 32669205.
In vitro protocol:	1. Deng CY, Lin SG, Zhang WC, Kuang SJ, Qian WM, Wu SL, Shan ZX, Yang M, Yu XY. Esmolol inhibits Na+ current in rat ventricular myocytes. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702. doi: 10.1358/mf.2006.28.10.1037498. PMID: 17235414. 2. Gorelik J, Vodyanoy I, Shevchuk AI, Diakonov IA, Lab MJ, Korchev YE. Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay. FEBS Lett. 2003 Jul 31;548(1-3):74-8. doi: 10.1016/s0014-5793(03)00743-9. PMID: 12885410.
In vivo protocol:	1. Ruggeri L, Nespoli F, Ristagno G, Fumagalli F, Boccardo A, Olivari D, Affatato R, Novelli D, De Giorgio D, Romanelli P, Minoli L, Cucino A, Babini G, Staszewsky L, Zani D, Pravettoni D, Belloli A, Scanziani E, Latini R, Magliocca A. Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. Sci Rep. 2021 May 20;11(1):10635. doi: 10.1038/s41598-021-90202-w. PMID: 34017043; PMCID: PMC8138021. 2. Hoareau GL, Beyer CA, Caples CM, Spruce MW, Gilbert Z, Grayson JK, Neff LP, Williams TK, Johnson MA. Esmolol reduces myocardial injury induced by resuscitative endovascular balloon occlusion of the aorta (REBOA) in a porcine model of hemorrhagic shock. Injury. 2020 Oct;51(10):2165-2171. doi: 10.1016/j.injury.2020.07.005. Epub 2020 Jul 3. PMID: 32669205.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zhao B, Sun W. Incompatibility of esmolol hydrochloride and furosemide in a
central venous access port. Am J Health Syst Pharm. 2014 Jun 1;71(11):901-2. doi:
10.2146/ajhp130526. PubMed PMID: 24830993.

2: Baaske DM, Dykstra SD, Wagenknecht DM, Karnatz NN. Stability of esmolol
hydrochloride in intravenous solutions. Am J Hosp Pharm. 1994 Nov
1;51(21):2693-6. PubMed PMID: 7856582.

3: Vucevic M, Purdy GM, Ellis FR. Esmolol hydrochloride for management of the
cardiovascular stress responses to laryngoscopy and tracheal intubation. Br J
Anaesth. 1992 May;68(5):529-30. PubMed PMID: 1642945.

4: Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE.
Stability of esmolol hydrochloride and sodium nitroprusside in intravenous
admixtures. Am J Hosp Pharm. 1989 Jan;46(1):101-4. PubMed PMID: 2565685.

5: Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol
hydrochloride and various injectable drugs during simulated Y-site injection. Am
J Hosp Pharm. 1988 Mar;45(3):630-2. Erratum in: Am J Hosp Pharm 1988
Jun;45(6):1281. PubMed PMID: 2897164.

6: Wiest DB, Garner SS, Childress LM. Stability of esmolol hydrochloride in 5%
dextrose injection. Am J Health Syst Pharm. 1995 Apr 1;52(7):716-8. PubMed PMID:
7627740.

7: Jordan D, Shulman SM, Miller ED Jr. Esmolol hydrochloride, sodium
nitroprusside, and isoflurane differ in their ability to alter peripheral
sympathetic responses. Anesth Analg. 1993 Aug;77(2):281-90. PubMed PMID: 8102224.

8: Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of
esmolol hydrochloride in the presence of aminophylline, bretylium tosylate,
heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm. 1990
Jul;47(7):1567-71. PubMed PMID: 2368749.

9: Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. Compatibility of esmolol
hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site
administration. Am J Hosp Pharm. 1988 Feb;45(2):368-71. PubMed PMID: 2896460.

10: Thompson DF, Thompson GD. Visual compatibility of esmolol hydrochloride and
furosemide in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm.
1987 Dec;44(12):2740. PubMed PMID: 3434585.

11: Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an
ultrashort-acting, beta-adrenergic blocking agent. Clin Pharm. 1986
Apr;5(4):288-303. Review. PubMed PMID: 2871961.

12: Karnatz NN, Baaske DM, Herbranson DE, Eliason MS. High-performance liquid
chromatographic method for the determination of esmolol hydrochloride in
solutions and parenteral formulations. J Chromatogr. 1985 Aug 23;330(2):420-4.
PubMed PMID: 4066833.

13: Lee YC, Baaske DM, Alam AS. High-performance liquid chromatographic method
for the determination of esmolol hydrochloride. J Pharm Sci. 1984
Nov;73(11):1660-1. PubMed PMID: 6520778.

Your view history

Esmolol Hydrochloride featured